ArticleBMC genomics2015
Comparative genomics and biological characterization of sequential Pseudomonas aeruginosa isolates from persistent airways infection.
Article in BMC genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 45 citations in OpenAlex.
- Review
- Dual-action thioarylamide-based small molecules to target drug-resistant bacteria and chronic inflammation.iScience · 2025Article
- Pseudomonas aeruginosa infection exacerbates elastase induced lung damage: characterisation of a novel murine two-hit model of pulmonary infection.Respiratory research · 2025Article
- Intracellular Pseudomonas aeruginosa persist and evade antibiotic treatment in a wound infection model.PLoS pathogens · 2025Article
- Review
- Host-microbe interactions in chronic rhinosinusitis biofilms and models for investigation.Biofilm · 2023Review
- The Antimicrobial, Antibiofilm and Anti-Inflammatory Activities of P13#1, a Cathelicidin-like Achiral Peptoid.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Genomic and Functional Characterization of Longitudinal Pseudomonas aeruginosa Isolates from Young Patients with Cystic Fibrosis.Microbiology spectrum · 2023Article
- Comparative Genomics ofAntibiotics (Basel, Switzerland) · 2023Article
- Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis.Microbiology spectrum · 2023Article
- Towards Translation of PqsR Inverse Agonists: From In Vitro Efficacy Optimization to In Vivo Proof-of-Principle.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Mixed Populations and Co-Infection: Pseudomonas aeruginosa and Staphylococcus aureus.Advances in experimental medicine and biology · 2022Article
- Effect of iron chelation on anti-pseudomonal activity of doxycycline.International journal of antimicrobial agents · 2021Article
- Review
- Common Adaptive Strategies Underlie Within-Host Evolution of Bacterial Pathogens.Molecular biology and evolution · 2021Article
- From genotype to phenotype: adaptations ofMicrobial genomics · 2021Review
- How Bacterial Adaptation to Cystic Fibrosis Environment Shapes Interactions BetweenFrontiers in microbiology · 2021Review
- The Small RNA ErsA Impacts the Anaerobic Metabolism ofFrontiers in microbiology · 2021Article
- Repurposing the Veterinary Antibiotic Apramycin for Antibacterial and Antibiofilm Activity AgainstFrontiers in microbiology · 2021Article
- UnderstandingCells · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPseudomonas aeruginosa establishes life-long chronic airway infections in cystic fibrosis (CF) patients. As the disease progresses, P. aeruginosa pathoadaptive variants are distinguished from the initially acquired strain. However, the genetic basis and the biology of host-bacteria interactions leading to a persistent lifestyle of P. aeruginosa are not understood. As a model system to study long term and persistent CF infections, the P. aeruginosa RP73, isolated 16.9 years after the onset of airways colonization from a CF patient, was investigated. Comparisons with strains RP1, isolated at the onset of the colonization, and clonal RP45, isolated 7 years before RP73 were carried out to better characterize genomic evolution of P. aeruginosa in the context of CF pathogenicity.
resultsVirulence assessments in disease animal model, genome sequencing and comparative genomics analysis were performed for clinical RP73, RP45, RP1 and prototype strains. In murine model, RP73 showed lower lethality and a remarkable capability of long-term persistence in chronic airways infection when compared to other strains. Pathological analysis of murine lungs confirmed advanced chronic pulmonary disease, inflammation and mucus secretory cells hyperplasia. Genomic analysis predicted twelve genomic islands in the RP73 genome, some of which distinguished RP73 from other prototype strains and corresponded to regions of genome plasticity. Further, comparative genomic analyses with sequential RP isolates showed signatures of pathoadaptive mutations in virulence factors potentially linked to the development of chronic infections in CF.
conclusionsThe genome plasticity of P. aeruginosa particularly in the RP73 strain strongly indicated that these alterations may form the genetic basis defining host-bacteria interactions leading to a persistent lifestyle in human lungs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.